CYP2D6 rs41475656: Defining the *41 Allele and Drug Metabolism

What each genotype means

Molecular Profile and Splicing Impact of rs41475656

The single-nucleotide polymorphism rs41475656 (historically annotated as 2988G>A or 2850C>T in various genomic references) resides within an intronic region of the CYP2D6 gene on chromosome 22. Although it does not directly alter an amino acid residue within the protein sequence, it disrupts consensus mRNA splicing. This aberrant splicing leads to significantly decreased expression of functional mature messenger RNA and, consequently, lower levels of the functional cytochrome P450 2D6 enzyme. Within the standardized nomenclature maintained by pharmacogenomics consortia, this variant is recognized as the key defining marker of the CYP2D6*41 reduced-function allele. Unlike complete null alleles that yield zero enzyme activity, *41 retains residual catalytic capacity. In clinical activity scoring models maintained by expert consensus bodies like the Clinical Pharmacogenetics Implementation Consortium (CPIC), the *41 allele is typically assigned a reduced activity score of 0.5, compared to an activity score of 1.0 for a standard reference wild-type allele.

The Biological Role of the CYP2D6 Enzyme

The CYP2D6 gene encodes cytochrome P450 family 2 subfamily D member 6, a crucial heme-containing monooxygenase primarily expressed in hepatocytes. Despite representing only a modest percentage of total hepatic cytochrome P450 protein content, CYP2D6 is responsible for the Phase I oxidative biotransformation of approximately 20 to 25 percent of all clinically utilized prescription drugs. Its substrates span diverse therapeutic domains, including central nervous system agents, tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), beta-blockers, antiarrhythmics, and analgesics. Depending on whether a drug is active in its parent form or requires enzymatic conversion to become potent, CYP2D6 acts either as an elimination pathway or as an activating catalyst. For prodrugs such as codeine (converted into morphine) or tamoxifen (converted into endoxifen), adequate CYP2D6 activity is required to generate therapeutic concentrations. For drugs directly cleared by the enzyme, diminished activity results in prolonged drug half-life and elevated systemic drug exposure.

Clinical Evidence: Intermediate Metabolism and Drug Response

Decades of peer-reviewed pharmacological studies have established moderate to strong evidence associating rs41475656 and the CYP2D6*41 allele with altered drug response phenotypes. Clinically, patient phenotypes are categorized into poor, intermediate, normal, and ultrarapid metabolizers. A carrier of the *41 allele paired with a fully non-functional allele (such as *4 or *5) or another reduced-function allele commonly presents with an intermediate metabolizer (IM) phenotype. For prodrug analgesics like codeine, tramadol, and hydrocodone, intermediate metabolizers generate lower peak levels of active opioid metabolites, frequently resulting in inadequate pain relief. Conversely, for medications deactivated by CYP2D6—such as the SSRIs paroxetine and fluvoxamine, or tricyclic antidepressants like amitriptyline—reduced clearance can cause higher blood concentrations, elevating the risk of adverse drug events. In oncology, intermediate metabolism correlates with lower endoxifen concentrations during adjuvant tamoxifen therapy, which has prompted clinical trials evaluating dose escalation or alternative therapies.

Population Distribution and Ancestral Patterns

The prevalence of rs41475656 varies considerably across global ancestral populations, reflecting the profound evolutionary divergence observed across the CYP2D6 locus. The variant allele is most frequently identified in populations of European and Middle Eastern descent, where minor allele frequencies routinely range between 8% and 10%. It is also observed at moderate frequencies among Central and South Asian cohorts. In contrast, rs41475656 is present at substantially lower frequencies in East Asian populations, where alternative reduced-function alleles (notably CYP2D6*10) predominate, and in sub-Saharan African populations, where alleles such as CYP2D6*17 and *29 serve as primary contributors to reduced enzymatic activity. Because different populations harbor distinct reduced-function or non-functional alleles, comprehensive multi-gene or star-allele testing panels are required to accurately interpret an individual's metabolic profile rather than testing a single variant in isolation.

Interpreting Results in Clinical Practice

Finding the rs41475656 variant in your genetic profile does not represent a medical diagnosis, nor does it guarantee you will experience drug side effects or treatment failure. Clinical drug response depends on multiple variables, including kidney function, liver health, age, adherence, and drug-drug interactions. Concomitant administration of strong CYP2D6 inhibitors—such as bupropion or fluoxetine—can functionally suppress enzyme activity, converting an intermediate metabolizer into a 'phenotypic' poor metabolizer, a phenomenon known as phenoconversion. Furthermore, CYP2D6 genotyping panels must evaluate copy number variations, such as gene deletions (*5) or duplications (*1xN, *2xN), to generate an accurate total activity score. Individuals should never discontinue, modify, or begin any prescription medication based on personal genomic data alone. Any adjustments to pharmacological regimens must be made under the clinical supervision of a prescribing physician or pharmacogenomics specialist.

Frequently asked questions

Sources & further reading